Novo's acquisition has legal ramifications: Dicerna sued by shareholders
A number of shareholders in US-based Dicerna have sued over an alleged breach of the US Securities Exchange Act, following the announcement of Novo Nordisk's planned acquisition of the US-based biotech firm.
by marketwire, translated by daniel pedersen
Novo Nordisk's acquisition of US-based biotech firm Dicerna for USD 3.3bn has been hit by a legal aftermath. Shareholders in Dicerna have filed separate suits against the firm and its board of directors, alleging violations of the US Securities Exchange Act, reports Law Street Media.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
.jpg&w=384&q=75)
